

The Association between Ultra-Processed Foods and Conventional Markers of Cardiovascular Risk in an Adult Iranian Population

Mehran Nouri, Ian G. Davies, Richard J. Webb, Mohsen Mazidi, Maede Makhtoomi, Abbas Rezaianzadeh, Masoumeh Ghodusi Johari, Shiva Faghih

PII: S0939-4753(23)00242-9

DOI: https://doi.org/10.1016/j.numecd.2023.06.009

Reference: NUMECD 3347

To appear in: *Nutrition, Metabolism and Cardiovascular Diseases*

Received Date: 26 October 2022

Revised Date: 8 June 2023

Accepted Date: 12 June 2023

Please cite this article as: Nouri M, Davies IG, Webb RJ, Mazidi M, Makhtoomi M, Rezaianzadeh A, Johari MG, Faghih S, The Association between Ultra-Processed Foods and Conventional Markers of Cardiovascular Risk in an Adult Iranian Population, *Nutrition, Metabolism and Cardiovascular Diseases*, https://doi.org/10.1016/j.numecd.2023.06.009.



The Association between Ultra-Processed Foods and Conventional Markers of Cardiovascular Risk in an Adult Iranian Population.

Mehran Nouri[1,2,3], Ian G. Davies[4], Richard J. Webb[5], Mohsen Mazidi[6], Maede Makhtoomi[2,3], Abbas Rezaianzadeh[7], Masoumeh Ghodusi Johari[8], Shiva Faghih[1,9,*]

[1]Department of Community Nutrition, School of Nutrition and Food Science, Shiraz University of Medical Sciences, Shiraz, Iran
[2]Health Policy Research Center, Institute of Health, Shiraz University of Medical Sciences, Shiraz, Iran
[3]Students' Research Committee, Shiraz University of Medical Sciences, Shiraz, Iran
[4]Research Institute of Sport and Exercise Science, Liverpool John Moores University, Liverpool, L3 3AF, UK.
[5]Faculty of Science, Hope Park Campus, School of Health and Sport Sciences, Liverpool Hope University, Taggart Avenue, Liverpool L16 9JD, UK.
[6]Nuffield Department of Population Health, Richard Doll Building, Old Road Campus, University of Oxford, Oxford OX3 7LF, UK.
[7]Department of Epidemiology, School of Health and Nutrition, Shiraz University of Medical Sciences, Shiraz, Iran
[8]Breast Diseases Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
[9]Nutrition Research Center, Shiraz University of Medical Sciences, Shiraz, Iran

***Correspondence to:** Shiva Faghih

Email: shivafaghih@gmail.com

Running title: Ultra-processed food and Conventional Markers of Cardiovascular Risk

Words: 3525 – Tables: 3 – Figure: 1

Abstract:

Background and Aims: According to the NOVA classification system, ultra-processed foods result from extensive industrial processing and use ingredients derived from food and non-food products, which can negatively impact on cardiovascular disease risk factors. Despite this, few studies have investigated UPFs in Middle Eastern populations regardless of high consumption in this region.

Methods and Results: This cross-sectional study was conducted on data from the Prospective Epidemiological Research Studies in Iran Kharemeh cohort (n = 6611). Food frequency questionnaires were assessed and the ratio of total UPFs energy/total energy intake was calculated. Data was categorized into tertiles of UPF consumption using the NOVA classification system. Kruskal–Wallis tests were used to assess differences in nutrient and food intakes between tertiles and logistic regression analysis was applied to assess the associations between UPFs and CVD risk factors. After adjustment for potential confounders the logistic regression analysis revealed significant positive relationships between intakes of UPFs and waist circumference (WC) (T_2: OR; 1.34, 95% CI; 1.13-1.60 – T_3: OR; 1.41, 95% CI; 1.18-1.69, P <0.001), low-density lipoprotein cholesterol (LDL-C) (T_2: OR; 1.20, 95% CI; 1.05-1.37 – T_3: OR; 1.27, 95% CI; 1.11-1.45, P <0.001), non-high-density lipoprotein cholesterol (non-HDL) (T_2: OR; 1.21, 95% CI; 1.07-1.37 – T_3: OR; 1.24, 95% CI; 1.10-1.41, P <0.001) and LDL-C to HDL-C ratio (T_2: OR; 1.15, 95% CI; 1.02-1.31 – T_3: OR; 1.21, 95% CI; 1.07-1.38, P = 0.002).

Conclusion: The consumption of UPFs was positively associated with WC and atherogenic blood lipids. However, increased intakes of fiber and unsaturated fats were also found in those consuming more UPFs, which was not expected. These findings offer insights into an understudied population and warrant further research.

Key words: ultra-processed food, cardiovascular disease, risk factors, adult, Iran

Introduction

Foods can be prepared in myriad ways, ranging from using minimal processing techniques, such as freezing, pasteurization, and fermentation, through to ultra-processing techniques involving chemical modification, extrusion, or the use of multiple treatments employed in tandem [1]. Many of these products are often highly palatable, convenient, and typically designed to

maximize industry profitability [2]. Examples of ultra-processed foods (UPFs) include soft drinks, ice-cream, and pre-prepared items such as pizzas and pies and can also consist of food products sometimes regarded as healthy, including flavored yoghurts and breakfast cereals [2]. Given the heterogeneity of UPFs the NOVA classification system has been developed to enable food items to be categorized into four groups based upon the level of processing they have undergone [3]. According to the NOVA classification, UPFs are defined as formulations which contain little to no intact foods, as well as fats, salt, sugar, stabilizers, colorings, preservatives and emulsifiers added by manufacturers [2]. Furthermore, foods which contain at least one item associated with an UPF group would be regarded as an UPF [2]. However, despite the development and widespread usage of the system few studies have utilized the NOVA classification to investigate the consumption and health impact of UPFs in ethnically diverse populations.

This is concerning when considering that findings from the National Health and Nutrition Examination Survey (NHANES) and the Spanish Seguimiento Universidad de Navarra (SUN) cohort study have both demonstrated that UPF consumption is associated with an increased risk of all-cause mortality [4, 5]. Furthermore, a recent dose-response meta-analysis which attempted to quantify the magnitude of response to UPFs revealed that for every 10% increase in UPF consumption, there is a 15% increase in all-cause mortality risk and a positive linear association with CVD-cause mortality [6]. These links with UPFs and increased risks of CVD have also been shown in several other large-scale cohort studies. Examples being the NutriNet-Santé cohort study, which found that the consumption of UPFs is significantly associated with increased cardiovascular, cerebrovascular, and coronary heart diseases, even after adjustment for known risk factors [7]. Similarly, the Framingham Offspring Study showed that each additional serving of UPFs consumed per day increased the likelihood of hard CVD (i.e. sudden and non-sudden coronary death, myocardial infarction, and fatal/nonfatal stroke), hard coronary heart disease and overall CVD and CVD mortality by 7%, 9% and 5% respectively [8]. The Italian Moli-Sani study also revealed that consuming UPFs is associated with an increased risk of CVD and all-cause mortality in individuals with a history of CVD, and for the first time highlighted the public health implications of UPFs specifically regarding secondary CVD prevention [9].

Due to these relationships, several biological mechanisms have been proposed. These include dyslipidemia and insulin resistance resulting from the excess energy, fat, sugar, and refined

carbohydrates which are abundant in UPFs [1]. High levels of sodium and additives may also promote hypertension and oxidative stress respectively and changes to the matrix of UPFs may render them more readily absorbed, negatively impacting upon glycemic responses and the gut microbiota, contributing to increased CVD risk [1]. Furthermore, indirect effects resulting from inadequate fruit, vegetable, and fiber intake in those who consume UPFs may be another contributing factor [1]. Consequently, organizations such as the American Heart Association have recommended individuals choose minimally processed foods as opposed to UPFs and in Latin America the avoidance of UPFs has been promoted as a 'Golden Rule' for dietary guidelines [2, 10].

Despite this progress little research regarding the impact of UPFs upon health has been conducted in the Middle East. This is particularly concerning since a global assessment of UPF consumption has shown increasing rates in the region [11] and a prospective cohort study of 21 countries highlighted that the Middle East had the second highest consumption of refined sweetened foods [12]. Also, a systematic review and meta-analysis of Iranian children showed high levels of sugar and fat consumption [13]. In terms of disease, a study of 139 healthy Iranian adolescents revealed increased DNA damage (as determined by 8-hydroxy-2 0-deoxyguanosine concentration) with increased UPF intake [14]. The relationship between UPFs and adiposity is unclear. For example, despite Iranians consuming a fifth of energy from UPF it appears that the relationship may be sex specific, with a positive association between UPF intake and overweight only existing in males [15]. However, this is not in agreement with data from a multi-national European cohort study, with similar positive associations between UPF consumption and weight gain being observed regardless of sex [16]. Paradoxical findings such as these suggest further work is required in ethnically diverse populations to account for cultural differences and unique dietary intakes. More broadly, the dearth of research investigating the impact of UPFs upon CVD in the Middle East warrants urgent attention.

Method

Study Design, Study Population & Covariates

The cross-sectional Prospective Epidemiological Research Studies in Iran (PERSIAN) [17], Kharameh cohort is a subgroup of PERSIAN conducted between 2014 and 2017 on a total of 10663 subjects aged 40–70 years [18]. After we excluded based on disease history, missing data,

and reporting of under- and over-nutrition, 6611 participants were included in our final analysis. Eligible individuals were included in the study by census method. As part of the PERSIAN cohort study, demographic information, physical activity, smoking status, and medical history were collected. In addition, weight, height, waist circumference (WC), hip circumference (HC), systolic blood pressure, and diastolic blood pressure, biochemical assessments including fasting blood glucose (FBS), total cholesterol (TC), triglyceride (TG), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C) and diet were measured.

Among the participants of the Kharameh cohort, those who had one or more types of cardiovascular diseases (CVDs) [19], hypertension, diabetes, other diseases, and an energy intake of less than 800 kcal or more than 4200 kcal were excluded (Figure 1). The study was approved by the ethics committee of Shiraz University of Medical Sciences, Fars, Iran (code: IR.SUMS.REC.1399.1115).



Figure 1. Flow diagram of the study.

Dietary Intake Assessment

Food intake was collected using a semi-quantitative 130-question food frequency questionnaire (FFQ), that was validated based upon the food habits and culture of the Iranian population [20]. Based on home scales, the recorded values of each food item in the FFQ were converted to grams. Nutritionist IV software for Iranians (version 7.0; N-Squared Computing, Salem, OR, USA) was used to calculate energy, macro- and micronutrients [21]. Finally, to calculate the ultra-processed foods index we selected food items which were defined as UPFs by the NOVA classification system. Then the total daily consumption of each UPF item was calculated based on their energy contribution (UPF items included: processed meats, confectionary, biscuits, cakes, pastries and sweets, buns, packaged breads, ice cream, sweetened milk-based beverages, industrial fruits drinks, salty snacks, margarine, fries, soft drinks, sauces and dressings etc.).These were divided into 8 subgroups (non-dairy beverages, cakes and cookies, dairy beverages, fast food and processed meats, oil and sauce, sweets, breads, and others). To understand the contribution of each food group to the total intake of highly processed foods the average daily energy intake of each of the 8 subgroups of UPFs was divided by the total daily energy intake of UPFs and multiplied by 100 [2, 22, 23]. As an exposure, we used a ratio based on the percentage of total calories from UPFs divided by total caloric intake. Also, to demonstrate the effect of UPFs and their poor nutritional quality, a healthy diet index was calculated based on 9 items (fruits and vegetables, pulses, nuts and seeds, protein, carbohydrate, fiber, saturated fatty acids (SFA), monounsaturated fatty acids (MUFA), polyunsaturated fatty acids (PUFA) and cholesterol intake) and we adjusted our results based upon this index (i.e. if the diet aligned with any of the 9 recommended components a score of 1 was given, otherwise, a score of 0 was applied) [24].

Anthropometric and Biochemical Assessments

The height, weight, WC, HC, and blood pressure of the participants were measured by trained experts. Weight was measured while wearing light clothing and height was measured without shoes. The accuracy of weight, HC and WC measurements were all within 0.1 cm accuracy. Body mass index (BMI) was calculated by dividing weight by the square of height (m). Blood pressure was measured after 10 minutes of rest in a sitting position using a calibrated German standard Reiser model sphygmomanometer. For laboratory evaluations, after 10-14 hours fasting, a 20 ml blood sample was taken from each participant and stored at -80°C prior to further analysis.

Glucose, TG, and TC were measured using a Mindray device (Japan) and Pars test kits. HDL-C, TG and TC levels were determined using enzymatic methods. The Friedwald formula was used to calculate LDL-C levels [25]. We dichotomized CVD risk factors based on: WC ≥ 88 cm for women and 102 for men, FBS ≥ 126 mg/dL, TG ≥ 150 mg/dL, TC ≥ 200 mg/dL L, LDL-C ≥ 130 mg/dL, HDL-C < 40 mg/dL for men and 50 mg/dL for women, and non-HDL-C ratio ≥ 130 were classed as abnormalities [21, 26-29].

Statistical Analysis

Demographic characteristics including age, gender, and education level of the participants were collected using a questionnaire. The educational level of the participants was determined by asking for the number of years spent in education. Physical activity was evaluated by using a questionnaire which included the time spent on various activities such as exercise, work, sleep, and eating during the day [19]. The metabolic equivalent of task (MET) was calculated for each activity. Finally, the total amount of metabolic equivalent of task (hours/day) was calculated for each participant [19].

All data were analyzed using SPSS software (version 20.0) and a P-value less than 0.05 was considered significant. The normality distribution of the variables was determined using the Kolmogorov-Smirnov test. First, we obtained energy-adjusted intakes of all food items using residual methods [30]. To compare the baseline characteristics of the participants one-way ANOVA or Chi-square tests were used for continuous and categorical variables respectively. Kruskal–Wallis tests were used to compare the intake of nutrients and food groups across tertiles of UPF intake. Three different multivariate logistic regression models were used to evaluate the relationship between the ultra-processed foods index and the odds of CVD risk factors. We chose to use three different models because some outcomes were dependent on BMI or gender. We used gender, age, physical activity, education, BMI status, and healthy diet index as confounding factors for the regression models.

Results

Baseline characteristics of the study population are shown in **Table 1**. There were significant differences in terms of gender (P <0.001), age (P <0.001), weight (P <0.001), BMI (P = 0.001), WC (P = 0.001), HC (P <0.001), education (P <0.001), systolic blood pressure (P = 0.043), TG

(P = 0.023), LDL-C (P = 0.004), HDL-C (P <0.001), non-HDL-C (P = 0.001) and LDL-C to HDL-C ratio (P <0.001) between tertiles of UPFs.

Higher consumption of UPFs were associated with higher intakes of energy, fat, fiber, cholesterol, MUFA, PUFA, non-dairy beverages, cookies and cakes, processed meat and fast food, margarine, and sauces and sweets, but lower intakes of protein, carbohydrate, and dairy products (P <0.001 for all) **(Table 2)**.

Multivariable-adjusted odds ratio (OR) and 95% confidence intervals [31] for outcomes through UPFs tertiles are displayed in **Table 3**. In the crude model, the population in the second and last tertiles of UPFs were more likely to have higher odds of WC (T_2: OR; 1.25, 95% CI; 1.11-1.40 – T_3: OR; 1.23, 95% CI; 1.09-1.39, P <0.001), TG (T_3: OR; 1.18, 95% CI; 1.03-1.36, P = 0.014), LDL-C (T_2: OR; 1.23, 95% CI; 1.08-1.40, P = 0.001), HDL-C (T_2: OR; 1.16, 95% CI; 1.10-1.40 – T_3: OR; 1.25, 95% CI; 1.11-1.41, P <0.001), non-HDL-C (T_2: OR; 1.25, 95% CI; 1.10-1.40 – T_3: OR; 1.24, 95% CI; 1.10-1.41, P <0.001) and LDL-C to HDL-C ratio (T_2: OR; 1.22, 95% CI; 1.08-1.37 – T_3: OR; 1.29, 95% CI; 1.15-1.46, P <0.001) abnormalities compared to those in the first tertile. Moreover, after adjustment for potential confounders in the full adjusted model, positive relationships among intakes of UPFs and WC (T_2: OR; 1.34, 95% CI; 1.13-1.60 – T_3: OR; 1.41, 95% CI; 1.18-1.69, P <0.001), LDL-C (T_2: OR; 1.20, 95% CI; 1.05-1.37 – T_3: OR; 1.27, 95% CI; 1.11-1.45, P <0.001), non-HDL-C (T_2: OR; 1.21, 95% CI; 1.07-1.37 – T_3: OR; 1.24, 95% CI; 1.10-1.41, P <0.001) and LDL-C to HDL-C ratio (T_2: OR; 1.15, 95% CI; 1.02-1.31 – T_3: OR; 1.21, 95% CI; 1.07-1.38, P = 0.002) abnormalities remained significant.

Discussion

Our study aimed to address the dearth of literature concerning the impact of UPF consumption upon markers of CVD in a Middle Eastern population. We showed that an increased intake of UPFs was positively associated with WC and increased odds of a poorer overall blood lipid profile. These are findings which, although being described by others [32], have not been widely reported in a Middle Eastern population. We also found several dietary abnormalities, but no evidence to support a relationship between UPF consumption and glycemic control.

The positive relationship between UPF consumption and WC partially agrees with the literature. For example, several studies have failed to show an association between UPFs and

numerous measures of adiposity, including ectopic fat, subcutaneous adipose tissue, total fat [33] and BMI, even after adjusting for physical activity [34]. Furthermore, a recent study conducted in Iranian children also revealed no associations between UPFs and measures of overweight and obesity [35]. These findings contrast with ours and the work of others, with one recent meta-analysis showing that the consumption of UPFs is associated with a 39% increased risk of overweight/obesity and greater waist circumference [36] and another showing an increased risk of overweight, obesity, and abdominal obesity [37]. A cross-sectional analysis of baseline data from the PREDIMED-PLUS trial also revealed direct associations between UPF consumption and weight using four different UPF classification systems and BMI when using the NOVA system [38]. Despite these contrary findings, it is important to note that most available evidence is observational. Currently only one randomized controlled trial (RCT) has been conducted (which took place in a metabolic ward setting) and found that energy intake and weight gain were both greater when consuming a diet of UPFs compared to a diet rich in whole foods [39]. Consequently, the authors recommended that the intake of UPFs should be limited in the context of obesity prevention and treatment [39].

With respect to other risk factors, our findings showed that the consumption of UPFs increased the odds of higher LDL-C, non-HDL-C and LDL-C to HDL-C ratio abnormalities. The potential for increased levels of LDL-C and other apolipoprotein B-containing lipoprotein particles is concerning, especially given their clear role in cardiovascular disease [40]. In this context, our findings agree with previous studies. For example, a cohort study of Brazilian children showed that after 3-4 years of follow-up, UPF intake was a predictor of LDL-C and total cholesterol levels [41]. A more recent extension of this work also highlighted other changes to blood lipids and showed that after 3 years of follow-up, children in the highest tertile of UPF consumption had higher concentrations of blood TG; a finding reflected in our own data [42]. These longitudinal trends are suggestive of the ability of UPFs to modulate blood lipids after exposure and is a cause for concern given that dietary patterns adopted earlier in life can persist into adulthood [43].

Similarly, evidence shows UPFs are negatively associated with HDL-C [36]. This was found in our study with those in the third tertile having the lowest concentrations. This occurred despite significantly higher proportions of MUFA and PUFA in tertile 3 compared to the first tertile, although there is the possibility that some of these unsaturated fatty acids may be trans fats which

are still present in the Iranian diet despite government interventions [44]. This suggests that the impact of food processing may eclipse that of fat composition and may perhaps explain our findings. Despite this, our logistic regression analysis did not show a significant positive relationship between UPF consumption and HDL-C after adjustment for confounding factors.

The results from our logistic regression analysis also showed no significant associations between UPF consumption and FBS; a finding which is not concordant with the literature. Several large-scale European studies have demonstrated a significant positive relationship between UPF intake and Type 2 diabetes [31, 45, 46]. Potential mechanisms have also been proposed, which include the production of and exposure to endocrine disruptors which have been associated with diabetes and increased intakes of fructose contributing to the promotion of hepatic and whole-body insulin resistance [31, 47, 48]. The reason for this lack of agreement with the wider literature is unknown; however, we speculate that although those in the third tertile consumed higher levels of all UPF items apart from dairy products, many of which are likely to be high in sugar and fat, significantly higher levels of fiber were being consumed too. This finding was unexpected but given the ability of dietary fiber to regulate blood glucose and other markers of glycemic control provides a plausible rationale for the lack of association [49, 50]. Furthermore, this may be a finding unique to Iran due to the regional dietary pattern, elements of which are known to be rich in fiber [51].

Limitations and Strengths

Our study has several strengths, including the large sample size and the adjustments which were made for a variety of potentially limiting confounding factors. We recognized that UPF consumption and diet quality are inversely associated and so we adjusted our logistic regression analysis to account for a healthy diet index [52]. This allows us to theoretically infer that the associations found between UPF consumption and CVD risk markers are independent of the nutritional quality of UPFs and that the effects may result from non-nutritional mechanisms. This has also been postulated by others who have found that associations between UPFs and increased mortality may be explained by the high level of food processing rather than their poor nutrient quality [53]. Despite these aspects there are several limitations which should be mentioned. These include that the study was a cross-sectional, observational design and therefore does not offer any insights into the temporal effects of consuming UPFs. Furthermore, the study only recruited

participants from Kharameh County and may not be nationally representative [54]. Similarly, although several confounding variables were accounted for there may be others that were not acknowledged which may have influenced the findings. Furthermore, although diet was assessed using a FFQ these instruments have been known to suffer from recall bias and have not been designed specifically for dietary data collection for subsequent NOVA classification, thus some UPF items may not have been properly listed. Similarly, there are known issues with the NOVA classification system regarding the misclassification of food items by evaluators which may also have affected the findings; however, the classification is widely used and allows comparison with previous studies [55, 56].

Conclusions

In summary, our findings show that the consumption of UPFs is associated with several physiological and dietary abnormalities which are in turn associated with CVD. More specifically, these include positive associations with waist circumference and atherogenic blood lipids. However, several unexpected findings were revealed, including a positive relationship between UPF consumption and increased consumption of unsaturated fats and fiber in those consuming higher levels of UPFs, which is perhaps an artefact of a unique regional dietary pattern. These findings offer insights into an understudied population and highlight a need for further evidence, particularly of a longitudinal nature, to determine the impact of UPFs on markers of CVD.

Acknowledgments

This work was supported by the Deputy of Research and Technology, Shiraz University of Medical Sciences, Shiraz, Iran.

Disclosure statement

All authors declare that they have no conflict of interest.

Availability of data and materials

Data is available on request from the authors.

Funding: This study was financially supported by Shiraz University of Medical Sciences, Shiraz, Iran. Number: 27293.

Authors' contributions: M.N, I.D, R.W, and M.M; Contributed to writing the first draft. M.N, M.M, and M.G.J; Contributed to all data and statistical analysis, and interpretation of data. S.F. and A.R; Contributed to the research concept, supervised the work and revised the manuscript. All authors read and approved the final manuscript.

References

[1] Juul F, Vaidean G, Parekh N. Ultra-processed Foods and Cardiovascular Diseases: Potential Mechanisms of Action. Adv Nutr. 2021;12:1673-80.
[2] Monteiro CA, Cannon G, Levy RB, Moubarac J-C, Louzada ML, Rauber F, et al. Ultra-processed foods: what they are and how to identify them. Public health nutrition. 2019;22:936-41.
[3] Monteiro CA, Levy RB, Claro RM, Castro IR, Cannon G. A new classification of foods based on the extent and purpose of their processing. Cad Saude Publica. 2010;26:2039-49.
[4] Kim H, Hu EA, Rebholz CM. Ultra-processed food intake and mortality in the USA: results from the Third National Health and Nutrition Examination Survey (NHANES III, 1988-1994). Public Health Nutr. 2019;22:1777-85.
[5] Rico-Campà A, Martínez-González MA, Alvarez-Alvarez I, Mendonça RdD, de la Fuente-Arrillaga C, Gómez-Donoso C, et al. Association between consumption of ultra-processed foods and all cause mortality: SUN prospective cohort study. BMJ. 2019;365:l1949.
[6] Suksatan W, Moradi S, Naeini F, Bagheri R, Mohammadi H, Talebi S, et al. Ultra-Processed Food Consumption and Adult Mortality Risk: A Systematic Review and Dose-Response Meta-Analysis of 207,291 Participants. Nutrients. 2021;14.
[7] Srour B, Fezeu LK, Kesse-Guyot E, Allès B, Méjean C, Andrianasolo RM, et al. Ultra-processed food intake and risk of cardiovascular disease: prospective cohort study (NutriNet-Santé). BMJ. 2019;365:l1451.
[8] Juul F, Vaidean G, Lin Y, Deierlein AL, Parekh N. Ultra-Processed Foods and Incident Cardiovascular Disease in the Framingham Offspring Study. J Am Coll Cardiol. 2021;77:1520-31.
[9] Bonaccio M, Costanzo S, Di Castelnuovo A, Persichillo M, Magnacca S, De Curtis A, et al. Ultra-processed food intake and all-cause and cause-specific mortality in individuals with cardiovascular disease: the Moli-sani Study. Eur Heart J. 2022;43:213-24.
[10] Lichtenstein AH, Appel LJ, Vadiveloo M, Hu FB, Kris-Etherton PM, Rebholz CM, et al. 2021 Dietary Guidance to Improve Cardiovascular Health: A Scientific Statement From the American Heart Association. Circulation. 2021;144:e472-e87.
[11] Baker P, Machado P, Santos T, Sievert K, Backholer K, Hadjikakou M, et al. Ultra-processed foods and the nutrition transition: Global, regional and national trends, food systems transformations and political economy drivers. Obes Rev. 2020;21:e13126.
[12] Narula N, Wong ECL, Dehghan M, Mente A, Rangarajan S, Lanas F, et al. Association of ultra-processed food intake with risk of inflammatory bowel disease: prospective cohort study. BMJ. 2021;374:n1554.
[13] Babashahi M, Omidvar N, Yazdizadeh B, Heidari-Beni M, Joulaei H, Narmcheshm S, et al. Systematic review and meta-analysis of the most common processed foods consumed by Iranian children. East Mediterr Health J. 2021;27:918-30.

[14] Edalati S, Bagherzadeh F, Asghari Jafarabadi M, Ebrahimi-Mamaghani M. Higher ultra-processed food intake is associated with higher DNA damage in healthy adolescents. Br J Nutr. 2021;125:568-76.
[15] Haghighatdoost F, Atefi M, Mohammadifard N, Daryabeygi-Khotbehsara R, Khosravi A, Mansourian M. The Relationship between Ultra-processed Foods Consumption and Obesity Indicators in Iranian Adults. Nutrition, Metabolism and Cardiovascular Diseases. 2022.
[16] Cordova R, Kliemann N, Huybrechts I, Rauber F, Vamos EP, Levy RB, et al. Consumption of ultra-processed foods associated with weight gain and obesity in adults: A multi-national cohort study. Clin Nutr. 2021;40:5079-88.
[17] Poustchi H, Eghtesad S, Kamangar F, Etemadi A, Keshtkar A-A, Hekmatdoost A, et al. Prospective epidemiological research studies in Iran (the PERSIAN Cohort Study): rationale, objectives, and design. Am J Epidemiol. 2018;187:647-55.
[18] Rezaianzadeh A, Jafari F, Sadeghi SE, Rahimikazerooni S. The prevalence and predictors of pre-hypertension and hypertension in Kherameh cohort study: a population based study on 10,663 persons in south of Iran. J Hum Hypertens. 2021;35:257-64.
[19] Kazemi Karyani A, Karmi Matin B, Soltani S, Rezaei S, Soofi M, Salimi Y, et al. Socioeconomic gradient in physical activity: findings from the PERSIAN cohort study. BMC Public Health. 2019;19:1312.
[20] Poustchi H, Eghtesad S, Kamangar F, Etemadi A, Keshtkar AA, Hekmatdoost A, et al. Prospective Epidemiological Research Studies in Iran (the PERSIAN Cohort Study): Rationale, Objectives, and Design. Am J Epidemiol. 2018;187:647-55.
[21] Borazjani M, Nouri M, Venkatakrishnane K, Najafi M, Faghih S. Association of plant-based diets with lipid profile and anthropometric indices: a cross-sectional study. Nutrition & Food Science. 2022;52:830-42.
[22] Nouri M, Eskandarzadeh S, Makhtoomi M, Rajabzadeh-Dehkordi M, Omidbeigi N, Najafi M, et al. Association between ultra-processed foods intake with lipid profile: a cross-sectional study. Sci Rep. 2023;13:7258.
[23] Jafari F, Yarmand S, Nouri M, Nejad ET, Ramezani A, Sohrabi Z, et al. Ultra-Processed Food Intake and Risk of Colorectal Cancer: A Matched Case-Control Study. Nutrition and Cancer. 2023;75:532-41.
[24] Maynard M, Ness AR, Abraham L, Blane D, Bates C, Gunnell D. Selecting a healthy diet score: lessons from a study of diet and health in early old age (the Boyd Orr cohort). Public Health Nutr. 2005;8:321-6.
[25] Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clinical chemistry. 1972;18:499-502.
[26] Salcedo-Cifuentes M, Belalcazar S, Acosta EY, Medina-Murillo JJ. Conventional biomarkers for cardiovascular risks and their correlation with the Castelli Risk Index-Indices and TG/HDL-C. Archivos de Medicina (Manizales). 2020;20:11-22.
[27] Huang PL. A comprehensive definition for metabolic syndrome. Dis Model Mech. 2009;2:231-7.
[28] Wongcharoen W, Sutthiwutthichai S, Gunaparn S, Phrommintikul A. Is non-HDL-cholesterol a better predictor of long-term outcome in patients after acute myocardial infarction compared to LDL-cholesterol? : a retrospective study. BMC Cardiovasc Disord. 2017;17:10.

[29] Lotfi M, Nouri M, Turki Jalil A, Rezaianzadeh A, Babajafari S, Ghoddusi Johari M, et al. Plant-based diets could ameliorate the risk factors of cardiovascular diseases in adults with chronic diseases. Food Science & Nutrition. 2022.
[30] Willett W. Nutritional epidemiology: Oxford university press; 2012.
[31] Llavero-Valero M, Escalada-San Martín J, Martínez-González MA, Basterra-Gortari FJ, de la Fuente-Arrillaga C, Bes-Rastrollo M. Ultra-processed foods and type-2 diabetes risk in the SUN project: A prospective cohort study. Clin Nutr. 2021;40:2817-24.
[32] Crimarco A, Landry MJ, Gardner CD. Ultra-processed Foods, Weight Gain, and Co-morbidity Risk. Current Obesity Reports. 2022;11:80-92.
[33] Fridén M, Kullberg J, Ahlström H, Lind L, Rosqvist F. Intake of Ultra-Processed Food and Ectopic-, Visceral- and Other Fat Depots: A Cross-Sectional Study. Front Nutr. 2022;9:774718.
[34] Cunha DB, da Costa THM, da Veiga GV, Pereira RA, Sichieri R. Ultra-processed food consumption and adiposity trajectories in a Brazilian cohort of adolescents: ELANA study. Nutr Diabetes. 2018;8:28.
[35] Asgari E, Askari M, Bellissimo N, Azadbakht L. Association between Ultraprocessed Food Intake and Overweight, Obesity, and Malnutrition among Children in Tehran, Iran. Int J Clin Pract. 2022;2022:8310260.
[36] Pagliai G, Dinu M, Madarena MP, Bonaccio M, Iacoviello L, Sofi F. Consumption of ultra-processed foods and health status: a systematic review and meta-analysis. Br J Nutr. 2021;125:308-18.
[37] Lane MM, Davis JA, Beattie S, Gómez-Donoso C, Loughman A, O'Neil A, et al. Ultraprocessed food and chronic noncommunicable diseases: A systematic review and meta-analysis of 43 observational studies. Obes Rev. 2021;22:e13146.
[38] Martinez-Perez C, San-Cristobal R, Guallar-Castillon P, Martínez-González M, Salas-Salvadó J, Corella D, et al. Use of Different Food Classification Systems to Assess the Association between Ultra-Processed Food Consumption and Cardiometabolic Health in an Elderly Population with Metabolic Syndrome (PREDIMED-Plus Cohort). Nutrients. 2021;13.
[39] Hall KD, Ayuketah A, Brychta R, Cai H, Cassimatis T, Chen KY, et al. Ultra-Processed Diets Cause Excess Calorie Intake and Weight Gain: An Inpatient Randomized Controlled Trial of Ad Libitum Food Intake. Cell Metab. 2019;30:67-77.e3.
[40] Ference BA, Ginsberg HN, Graham I, Ray KK, Packard CJ, Bruckert E, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. European Heart Journal. 2017;38:2459-72.
[41] Rauber F, Campagnolo PD, Hoffman DJ, Vitolo MR. Consumption of ultra-processed food products and its effects on children's lipid profiles: a longitudinal study. Nutr Metab Cardiovasc Dis. 2015;25:116-22.
[42] Leffa PS, Hoffman DJ, Rauber F, Sangalli CN, Valmórbida JL, Vitolo MR. Longitudinal associations between ultra-processed foods and blood lipids in childhood. Br J Nutr. 2020;124:341-8.
[43] Movassagh EZ, Baxter-Jones ADG, Kontulainen S, Whiting SJ, Vatanparast H. Tracking Dietary Patterns over 20 Years from Childhood through Adolescence into Young Adulthood: The Saskatchewan Pediatric Bone Mineral Accrual Study. Nutrients. 2017;9.
[44] Stender S. Trans fat in foods in Iran, South-Eastern Europe, Caucasia and Central Asia: a market basket investigation. Food Policy. 2020;96:101877.

[45] Srour B, Fezeu LK, Kesse-Guyot E, Allès B, Debras C, Druesne-Pecollo N, et al. Ultraprocessed Food Consumption and Risk of Type 2 Diabetes Among Participants of the NutriNet-Santé Prospective Cohort. JAMA Intern Med. 2020;180:283-91.
[46] Levy RB, Rauber F, Chang K, Louzada MLdC, Monteiro CA, Millett C, et al. Ultra-processed food consumption and type 2 diabetes incidence: A prospective cohort study. Clin Nutr. 2021;40:3608-14.
[47] Gore AC, Chappell VA, Fenton SE, Flaws JA, Nadal A, Prins GS, et al. EDC-2: The Endocrine Society's Second Scientific Statement on Endocrine-Disrupting Chemicals. Endocr Rev. 2015;36:E1-e150.
[48] Jensen T, Abdelmalek MF, Sullivan S, Nadeau KJ, Green M, Roncal C, et al. Fructose and sugar: A major mediator of non-alcoholic fatty liver disease. J Hepatol. 2018;68:1063-75.
[49] Silva FM, Kramer CK, de Almeida JC, Steemburgo T, Gross JL, Azevedo MJ. Fiber intake and glycemic control in patients with type 2 diabetes mellitus: a systematic review with meta-analysis of randomized controlled trials. Nutr Rev. 2013;71:790-801.
[50] Mao T, Huang F, Zhu X, Wei D, Chen L. Effects of dietary fiber on glycemic control and insulin sensitivity in patients with type 2 diabetes: A systematic review and meta-analysis. J Funct Foods. 2021;82:104500.
[51] Aghayan M, Asghari G, Yuzbashian E, Mahdavi M, Mirmiran P, Azizi F. Secular trend in dietary patterns of Iranian adults from 2006 to 2017: Tehran lipid and glucose study. Nutr J. 2020;19:110.
[52] Martini D, Godos J, Bonaccio M, Vitaglione P, Grosso G. Ultra-Processed Foods and Nutritional Dietary Profile: A Meta-Analysis of Nationally Representative Samples. Nutrients. 2021;13.
[53] Bonaccio M, Di Castelnuovo A, Ruggiero E, Costanzo S, Grosso G, De Curtis A, et al. Joint association of food nutritional profile by Nutri-Score front-of-pack label and ultra-processed food intake with mortality: Moli-sani prospective cohort study. BMJ. 2022;378:e070688.
[54] Nikbakht HA, Rezaianzadeh A, Seif M, Ghaem H. Factor Analysis of Metabolic Syndrome Components in a Population-Based Study in the South of Iran (PERSIAN Kharameh Cohort Study). Iran J Public Health. 2021;50:1863-71.
[55] Bleiweiss-Sande R, Chui K, Evans EW, Goldberg J, Amin S, Sacheck J. Robustness of Food Processing Classification Systems. Nutrients. 2019;11.
[56] Braesco V, Souchon I, Sauvant P, Haurogné T, Maillot M, Féart C, et al. Ultra-processed foods: how functional is the NOVA system? Eur J Clin Nutr. 2022.

Table 1. Baseline characteristics of study participants.

	Ultra-processed Foods			
Variables	**T_1 (n=2295)**	**T_2 (n=2206)**	**T_3 (n=2110)**	**P-value**
Gender, male (%)	45.1	49.9	52.3	**<0.001**
Age (year)	51.16 ± 7.97	49.86 ± 7.60	49.08 ± 7.52	**<0.001**
Weight [40]	67.40 ± 12.30	68.86 ± 12.04	69.11 ± 12.07	**<0.001**
BMI (kg/m^2)	25.27 ± 4.40	25.74 ± 4.41	25.64 ± 4.42	**0.001**
WC (cm)	92.89 ± 11.89	94.10 ± 11.93	94.08 ± 12.05	**0.001**
HC (cm)	99.85 ± 8.27	100.79 ± 8.26	100.65 ± 8.15	**<0.001**
Education (year)	4.21 ± 4.33	5.23 ± 4.61	5.49 ± 4.57	**<0.001**
Physical Activity (met/day)	39.15 ± 6.34	38.77 ± 6.07	39.17 ± 6.61	0.062
Systolic Blood Pressure (mmHg)	111.15 ± 15.28	111.06 ± 15.06	110.11 ± 14.71	**0.043**
Diastolic Blood Pressure (mmHg)	70.42 ± 9.39	70.58 ± 9.46	70.18 ± 9.16	0.359
FBS (mg/dL)	91.43 ± 16.84	91.33 ± 15.61	90.68 ± 17.07	0.266
TG (mg/dL)	121.88 ± 80.54	122.97 ± 69.21	127.99 ± 83.59	**0.023**
TC (mg/dL)	186.54 ± 40.32	188.81 ± 39.60	189.00 ± 41.06	0.078
LDL-C (mg/dL)	113.52 ± 33.49	116.48 ± 33.37	116.39 ± 34.67	**0.004**
HDL-C (mg/dL)	48.80 ± 12.99	47.89 ± 12.58	47.24 ± 12.39	**<0.001**
Non-HDL-C	137.71 ± 38.71	140.94 ± 38.04	141.79 ± 39.63	**0.001**
LDL-C to HDL-C ratio	2.46 ± 0.91	2.56 ± 0.91	2.59 ± 0.91	**<0.001**
UPF intake (% energy)	5.60 ± 2.20	11.06 ± 1.61	20.50 ± 5.91	**<0.001**
UPF intake (kcal/day energy)	135.13 ± 71.25	272.27 ± 85.96	525.31 ± 212.70	**<0.001**

BMI, body mass index; WC, waist circumference; HC, hip circumference; FBS, fasting blood sugar; TG, triglyceride; TC, total cholesterol; LDL-C, low density lipoprotein-cholesterol; HDL-C, high density lipoprotein-cholesterol.
Values are mean ± SD for continuous and percentage for categorical variables.
P-values derived using one-way ANOVA for continuous and Chi-square tests for categorical variables.
Bold values show significant variables.

500 **Table 2.** Nutrients and food intakes between tertiles of UPFs.

	Ultra-processed Foods			
Variables	**T_1 (n=2295)**	**T_2 (n=2206)**	**T_3 (n=2110)**	**P-value**
Nutrients	**Median (25th-75th)**	**Median (25th-75th)**	**Median (25th-75th)**	
Energy (kcal/d)	2331.28 (1870.4-2858.2)	2395.79 (1944.1-2886.1)	2507.79 (2053.7-2998.1)	**<0.001**
Protein (%Energy)	12.86 (10.35-16.11)	12.57 (10.10-15.51)	11.87 (9.56-14.46)	**<0.001**
Carbohydrate (%Energy)	67.76 (55.45-84.61)	65.87 (53.95-80.15)	62.39 (50.73-75.83)	**<0.001**
Fat (%Energy)	9.99 (7.59-12.81)	10.12 (7.98-12.83)	10.33 (8.39-12.55)	**<0.001**
Fiber (g/day)	22.69 (19.68-26.69)	24.21 (20.98-28.18)	24.60 (21.10-28.69)	**<0.001**
Cholesterol (g/day)	216.29 (166.60-276.23)	237.26 (179.20-288.87)	242.19 (192.88-305.54)	**<0.001**
SFA (%Energy)	8.03 (5.89-10.65)	8.07 (6.11-10.35)	8.10 (6.33-10.28)	0.587
MUFA (%Energy)	6.19 (4.40-8.32)	6.62 (4.97-8.49)	6.96 (5.46-8.66)	**<0.001**
PUFA (%Energy)	3.28 (2.16-4.54)	3.65 (2.61-4.87)	4.04 (3.07-5.18)	**<0.001**
Food Items				
Non-dairy Beverage (%Energy)	4.70 (1.34-11.67)	7.01 (2.26-15.64)	8.36 (3.12-18.16)	**<0.001**
Cookies and cakes (%Energy)	14.55 (6.50-26.21)	20.48 (11.80-32.41)	28.72 (16.95-42.19)	**<0.001**
Dairy products (%Energy)	47.75 (30.72-63.66)	35.28 (24.40-46.30)	23.52 (15.26-33.71)	**<0.001**
Processed meat and fast food (%)	0.00 (0.00-3.17)	0.97 (0.00-4.71)	2.37 (0.00-8.52)	**<0.001**
Margarine and sauces (%Energy)	6.33 (2.11-13.80)	8.40 (3.51-16.67)	8.36 (3.53-16.35)	**<0.001**
Sweets (%Energy)	4.22 (1.15-9.02)	5.92 (2.57-10.95)	5.28 (2.59-9.56)	**<0.001**
Bread (%Energy)	0.33 (0.00-2.37)	0.82 (0.00-2.77)	0.80 (0.00-3.07)	**<0.001**
Others (%Energy)	1.61 (0.23-4.94)	1.92 (0.46-4.95)	1.65 (0.40-4.27)	**0.007**

501 UPFs, ultra-processed foods; SFA, saturated fatty acid; PUFA, polyunsaturated fatty acid; MUFA, monounsaturated
502 fatty acid.
503 P-values derived from Kruskal–Wallis tests.
504 Values reported median (percentile 25th-75th).
505 Bold values show significant variables.
506
507
508
509
510
511

Table 3. Crude and multivariable-adjusted odds ratios and 95% CIs across tertile of UPFs.

	Ultra-processed Foods			
Variables	**T_1 (n=2295)**	**T_2 (n=2206)**	**T_3 (n=2110)**	**P_{trend}**
WC (cm)				
Crude Model	Ref.	**1.25 (1.11, 1.40)**	**1.23 (1.09, 1.39)**	**<0.001**
Adjusted Model[a]	Ref.	**1.26 (1.12, 1.43)**	**1.27 (1.12, 1.44)**	**<0.001**
Adjusted Model[b]	Ref.	**1.34 (1.13, 1.60)**	**1.41 (1.18, 1.69)**	**<0.001**
FBS (mg/dL)				
Crude Model	Ref.	0.81 (0.49, 1.32)	0.82 (0.50, 1.34)	0.415
Adjusted Model[c]	Ref.	0.83 (0.51, 1.37)	0.87 (0.53, 1.45)	0.596
TG (mg/dL)				
Crude Model	Ref.	1.11 (0.97, 1.27)	**1.18 (1.03, 1.36)**	**0.014**
Adjusted Model[c]	Ref.	1.03 (0.89, 1.19)	1.10 (0.96, 1.28)	0.160
LDL-C (mg/dL)				
Crude Model	Ref.	**1.20 (1.05, 1.37)**	**1.23 (1.08, 1.40)**	**0.001**
Adjusted Model[c]	Ref.	**1.20 (1.05, 1.37)**	**1.27 (1.11, 1.45)**	**<0.001**
HDL-C (mg/dL)				
Crude Model	Ref.	**1.16 (1.03, 1.31)**	**1.25 (1.11, 1.41)**	**<0.001**
Adjusted Model[b]	Ref.	1.05 (0.93, 1.19)	1.12 (0.99, 1.27)	0.065
Non-HDL-C				
Crude Model	Ref.	**1.25 (1.10, 1.40)**	**1.24 (1.10, 1.40)**	**<0.001**
Adjusted Model[c]	Ref.	**1.21 (1.07, 1.37)**	**1.24 (1.10, 1.41)**	**<0.001**
LDL-C to HDL-C Ratio				
Crude Model	Ref.	**1.22 (1.08, 1.37)**	**1.29 (1.15, 1.46)**	**<0.001**
Adjusted Model[c]	Ref.	**1.15 (1.02, 1.31)**	**1.21 (1.07, 1.38)**	**0.002**

UPFs, ultra-processed foods; WC, waist circumference; FBS, fasting blood sugar; TG, triglyceride; LDL-C, low density lipoprotein-cholesterol; HDL-C, high density lipoprotein-cholesterol.
Dichotomized CVD risk factors based on: WC ≥ 88 cm for women and 102 for men, FBS ≥ 126 mg/dL, TG ≥ 150 mg/dL, TC ≥ 200 mg/dL L, LDL-C ≥ 130 mg/dL, HDL-C < 40 mg/dL for men and 50 mg/dL for women, and non-HDL ratio ≥ 130.
Adjusted Model[a]: adjusted for age, physical activity, education and healthy diet index.
Adjusted Model[b]: adjusted for age, physical activity, education, BMI and healthy diet index.
Adjusted Model[c]: adjusted for gender, age, physical activity, education, and healthy diet index.
Values are odd ratio (95% CIs).
P_{trend} obtained from logistic regression.
Bold values show significant variables.

Highlight

1- Ultra-processed foods (UPFs) that prepared in myriad ways, ranging from minimum processing techniques, can be effect on cardiovascular diseases (CVD) risk factors

2- Our findings show that the consumption of UPFs is associated with several physiological and dietary abnormalities which are in turn associated with CVD.

3- A positive associations with waist circumference and atherogenic blood lipids.

4- Increased consumption of unsaturated fats and fiber in those consuming higher levels of UPFs, which is perhaps an artefact of a unique regional dietary pattern.

ICMJE DISCLOSURE FORM

Date: 3/7/2023

Your Name: Mehran Nouri

Manuscript Title: The Association between Ultra-Processed Foods and Conventional Markers of Cardiovascular Risk in an Adult Iranian Population

Manuscript Number (if known): Click or tap here to enter text.

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Time frame: Since the initial planning of the work			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) **No time limit for this item.**	☒ None	
		Click the tab key to add additional rows.	
Time frame: past 36 months			
2	Grants or contracts from any entity (if not indicated in item #1 above).	☒ **None**	
3	Royalties or licenses	☒ **None**	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	☒ **None**	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	☒ **None**	
6	Payment for expert testimony	☒ **None**	
7	Support for attending meetings and/or travel	☒ **None**	
8	Patents planned, issued or pending	☒ **None**	
9	Participation on a Data Safety Monitoring Board or Advisory Board	☒ **None**	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	☒ **None**	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	☒ **None**	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	☒ **None**	
13	Other financial or non-financial interests	☒ **None**	

Please place an "X" next to the following statement to indicate your agreement:

☒ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

ICMJE DISCLOSURE FORM

Date: 3/7/2023

Your Name: Ian G. Davies

Manuscript Title: The Association between Ultra-Processed Foods and Conventional Markers of Cardiovascular Risk in an Adult Iranian Population

Manuscript Number (if known): Click or tap here to enter text.

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	**Specifications/Comments (e.g., if payments were made to you or to your institution)**
Time frame: Since the initial planning of the work			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) **No time limit for this item.**	☒ **None**	
		Click the tab key to add additional rows.	
Time frame: past 36 months			
2	Grants or contracts from any entity (if not indicated in item #1 above).	☒ **None**	
3	Royalties or licenses	☒ **None**	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	☒ **None**	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	☒ **None**	
6	Payment for expert testimony	☒ **None**	
7	Support for attending meetings and/or travel	☒ **None**	
8	Patents planned, issued or pending	☒ **None**	
9	Participation on a Data Safety Monitoring Board or Advisory Board	☒ **None**	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	☒ **None**	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	☒ **None**	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	☒ **None**	
13	Other financial or non-financial interests	☒ **None**	

Please place an "X" next to the following statement to indicate your agreement:

☒ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

ICMJE DISCLOSURE FORM

Date: 3/7/2023

Your Name: Richard J. Webb

Manuscript Title: The Association between Ultra-Processed Foods and Conventional Markers of Cardiovascular Risk in an Adult Iranian Population

Manuscript Number (if known): Click or tap here to enter text.

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Time frame: Since the initial planning of the work			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) **No time limit for this item.**	☒ None	
			Click the tab key to add additional rows.
Time frame: past 36 months			
2	Grants or contracts from any entity (if not indicated in item #1 above).	☒ **None**	
3	Royalties or licenses	☒ **None**	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	☒ **None**	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	☒ **None**	
6	Payment for expert testimony	☒ **None**	
7	Support for attending meetings and/or travel	☒ **None**	
8	Patents planned, issued or pending	☒ **None**	
9	Participation on a Data Safety Monitoring Board or Advisory Board	☒ **None**	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	☒ **None**	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	☒ **None**	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	☒ **None**	
13	Other financial or non-financial interests	☒ **None**	

Please place an "X" next to the following statement to indicate your agreement:

☒ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

ICMJE DISCLOSURE FORM

Date: 3/7/2023

Your Name: Mohsen Mazidi

Manuscript Title: The Association between Ultra-Processed Foods and Conventional Markers of Cardiovascular Risk in an Adult Iranian Population

Manuscript Number (if known): Click or tap here to enter text.

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Time frame: Since the initial planning of the work			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) **No time limit for this item.**	☒ None	
		Click the tab key to add additional rows.	
Time frame: past 36 months			
2	Grants or contracts from any entity (if not indicated in item #1 above).	☒ **None**	
3	Royalties or licenses	☒ **None**	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	☒ **None**	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	☒ **None**	
6	Payment for expert testimony	☒ **None**	
7	Support for attending meetings and/or travel	☒ **None**	
8	Patents planned, issued or pending	☒ **None**	
9	Participation on a Data Safety Monitoring Board or Advisory Board	☒ **None**	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	☒ **None**	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	☒ **None**	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	☒ **None**	
13	Other financial or non-financial interests	☒ **None**	

Please place an "X" next to the following statement to indicate your agreement:

☒ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

ICMJE DISCLOSURE FORM

Date: 3/7/2023

Your Name: Maede Makhtoomi

Manuscript Title: The Association between Ultra-Processed Foods and Conventional Markers of Cardiovascular Risk in an Adult Iranian Population

Manuscript Number (if known): Click or tap here to enter text.

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	**Specifications/Comments (e.g., if payments were made to you or to your institution)**
Time frame: Since the initial planning of the work			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) **No time limit for this item.**	☒ **None**	
			Click the tab key to add additional rows.
Time frame: past 36 months			
2	Grants or contracts from any entity (if not indicated in item #1 above).	☒ **None**	
3	Royalties or licenses	☒ **None**	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	☒ **None**	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	☒ **None**	
6	Payment for expert testimony	☒ **None**	
7	Support for attending meetings and/or travel	☒ **None**	
8	Patents planned, issued or pending	☒ **None**	
9	Participation on a Data Safety Monitoring Board or Advisory Board	☒ **None**	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	☒ **None**	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	☒ **None**	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	☒ **None**	
13	Other financial or non-financial interests	☒ **None**	

Please place an "X" next to the following statement to indicate your agreement:

☒ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

ICMJE DISCLOSURE FORM

Date: 3/7/2023

Your Name: Abbas Rezaianzadeh

Manuscript Title: The Association between Ultra-Processed Foods and Conventional Markers of Cardiovascular Risk in an Adult Iranian Population

Manuscript Number (if known): Click or tap here to enter text.

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Time frame: Since the initial planning of the work			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) **No time limit for this item.**	☒ None	
		Click the tab key to add additional rows.	
Time frame: past 36 months			
2	Grants or contracts from any entity (if not indicated in item #1 above).	☒ **None**	
3	Royalties or licenses	☒ **None**	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	☒ **None**	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	☒ **None**	
6	Payment for expert testimony	☒ **None**	
7	Support for attending meetings and/or travel	☒ **None**	
8	Patents planned, issued or pending	☒ **None**	
9	Participation on a Data Safety Monitoring Board or Advisory Board	☒ **None**	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	☒ **None**	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	☒ **None**	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	☒ **None**	
13	Other financial or non-financial interests	☒ **None**	

Please place an "X" next to the following statement to indicate your agreement:

☒ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

ICMJE DISCLOSURE FORM

Date: 3/7/2023

Your Name: Masoumeh Ghodusi Johari

Manuscript Title: The Association between Ultra-Processed Foods and Conventional Markers of Cardiovascular Risk in an Adult Iranian Population

Manuscript Number (if known): Click or tap here to enter text.

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Time frame: Since the initial planning of the work			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) **No time limit for this item.**	☒ None	
		Click the tab key to add additional rows.	
Time frame: past 36 months			
2	Grants or contracts from any entity (if not indicated in item #1 above).	☒ **None**	
3	Royalties or licenses	☒ **None**	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	☒ **None**	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	☒ **None**	
6	Payment for expert testimony	☒ **None**	
7	Support for attending meetings and/or travel	☒ **None**	
8	Patents planned, issued or pending	☒ **None**	
9	Participation on a Data Safety Monitoring Board or Advisory Board	☒ **None**	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	☒ **None**	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	☒ **None**	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	☒ **None**	
13	Other financial or non-financial interests	☒ **None**	

Please place an "X" next to the following statement to indicate your agreement:

☒ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

ICMJE DISCLOSURE FORM

Date: 3/7/2023

Your Name: Shiva Faghih

Manuscript Title: The Association between Ultra-Processed Foods and Conventional Markers of Cardiovascular Risk in an Adult Iranian Population

Manuscript Number (if known): Click or tap here to enter text.

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Time frame: Since the initial planning of the work			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) **No time limit for this item.**	☒ None	
		Click the tab key to add additional rows.	
Time frame: past 36 months			
2	Grants or contracts from any entity (if not indicated in item #1 above).	☒ **None**	
3	Royalties or licenses	☒ **None**	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	☒ **None**	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	☒ **None**	
6	Payment for expert testimony	☒ **None**	
7	Support for attending meetings and/or travel	☒ **None**	
8	Patents planned, issued or pending	☒ **None**	
9	Participation on a Data Safety Monitoring Board or Advisory Board	☒ **None**	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	☒ **None**	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	☒ **None**	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	☒ **None**	
13	Other financial or non-financial interests	☒ **None**	

Please place an "X" next to the following statement to indicate your agreement:

☒ I certify that I have answered every question and have not altered the wording of any of the questions on this form.